Last reviewed · How we verify

NCT06027788: EMPRO

CTSN Embolic Protection Trial

Recruiting now NA Last updated 20 July 2025
What this trial tests

NA trial testing CardioGard Embolic Protection Cannula in Delirium in 842 participants. Currently enrolling.

Timeline
18 September 2023
Primary endpoint
1 April 2027
1 April 2027

Quick facts

Lead sponsorIcahn School of Medicine at Mount Sinai
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposeprevention
Enrollment842
Start date18 September 2023
Primary completion1 April 2027
Estimated completion1 April 2027
Sites28 locations across Canada, United States

Drugs / interventions tested

Conditions studied

Sponsor

Icahn School of Medicine at Mount Sinai

Who can join

60 and older, any sex, with Delirium or Ischemic Stroke. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective, multi-center, randomized effectiveness trial of the CardioGard Embolic Protection Cannula in high-risk valve surgery patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Delirium

Currently open trials in the same condition.

Other Icahn School of Medicine at Mount Sinai trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06027788.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing